Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis

Gut

Volumn 38, Issue 5, 1996, Pages 649-654

  Holloway, R H ^a   Dent, J ^a   Narielvala, F ^b   Mackinnon, A M ^c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b Units Repatriation Hospital   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

gastric acid secretion; gastro oesophageal reflux; oesophagus; pH monitoring

Indexed keywords

OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENDOSCOPY; ESOPHAGUS PH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PH MEASUREMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH ACID SECRETION;

EID: 0029938339     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.5.649     Document Type: Article

References (37)

1. Joelsson B, Johnsson F. Heartburn - the acid test. Gut 1989; 30: 1523-5.
2. de Caestecker JS, Blackwell JN, Pryde A, Heading RC. Daytime gastro-oesophageal reflux is important in oesophagitis. Gut 1987; 28: 519-29.
3. Robertson D, Alersley JM, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987; 28: 1484-8.
4. Havelund T, Laursen LS, Skoubo-Kristensen E, Andersen BN, Pedersen SA, Jensen KB, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. BMJ 1988; 296: 89-92.
5. Dehn TCB, Sheperd HA, Colin-Jones D, Kettlewell MGW, Carroll NJH. Double blind comparison of omeprazole (40mg od) versus cimetidine (400mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut 1990; 31: 509-13.
6. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
7. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 625-32.
8. Sontag SJ, Hirschowitz BI, Holt S, Robinson MG, Behar J, Berenson MM, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 1992; 102: 109-18.
9. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts JL. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33: 523-9.
10. Zeitoun P. Comparison of omeprazole with ranitidine in the treatment of reflux oesophagitis. Scand J Gastroenterol 1989; 24: 83-7.
11. Bardhan KD, Morris P, Thompson M, Dhande DS, Hinchliffe RF, Jones RB, et al. Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine. Gut 1990; 31: 745-9.
12. Koop H, Hotz J, Pommer G, Klein M, Arnold R. Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4: 593-9.
13. Lundell L, Backman L, Ekstrom P, Enander LH, Fausa O, Lind T, et al. Omeprazole of high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to "standard doses" of H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4: 145-55.
14. Marciano-D'Amore DA, Paterson WG, Da-Costa LR, Beck IT. Omeprazole in H2 receptor antagonist-resistant reflux esophagitis. J Clin Gastroenterol 1990; 12: 616-20.
15. Bell N, Hunt R. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24.
16. Robertson D, Aldersley M, Shepherd H, Lloyd R, Smith R. H2 Antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response? Gut 1987; 28: 946-9.
17. Klinkenberg-Knol EC, Meuwissen SGM. Combined gastric and esophageal 24-hour pH monitoring and esophageal manometry in patients with reflux disease resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990; 4: 485-95.
18. Hirschowitz BI. Acid and pepsin secretion in patients with esophagitis refractory to treatment with 112 antagonists. Scand J Gastroenterol 1992; 27: 449-52.
19. Tytgat GN, Nicolai JJ, Reman FC. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 1990; 99: 629-34.
20. Lieberman DA. 24-hour esophageal pH monitoring before and after medical therapy for reflux esophagitis. Dig Dis Sci 1988; 33: 166-71.
21. Olden K, Triadafilopoulos G. Failure of initial 24-hour esophageal pH monitoring to predict refractoriness and intractability in reflux esophagitis. Am J Gastroenterol 1991; 86: 1142-6.
22. Bianchi-Porro G, Pace F, Sangaletti O. Pattern of acid reflux in patients with reflux esophagitis 'resistant' to H2-receptor antagonists. Scand J Gastroenterol 1990; 25: 810-4.
23. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990; 98: 654-61.
24. Frislid K, Aadland E, Berstad A. Augmented postprandial gastric secretion due to exposure to ranitidine in healthy subjects. Scand J Gastroenterol 1986; 21: 119-22.
25. Van de Mierop F, Flockhart D, Gallagher J, Maher K, Soukhova N, Gupta PK, et al. Omeprazole metabolism in refractory GERD: pharmacokinetics and pharmacodynamics [Abstract]. Gastroenterology 1995; 108: A249.
26. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58.
27. Barlow A, DeMeester T, Ball C, Eypasch E. The significance of the gastric secretory state in gastroesophageal reflux disease. Arch Surg 1989; 124: 937-40.
28. Mulholland MW, Reid BJ, Levine DS, Rubin CE. Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig Dis Sci 1989; 34: 1329-35.
29. Collen MJ, Johnson DA, Sheridan MJ. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy. Dig Dis Sci 1994; 39: 410-7.
30. Savarino V, Mela GS, Zentilin P, Cutela P, Mele MR, Vigneri S, et al. Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. Dig Dis Sci 1994; 39: 161-8.
31. Sharma BK, Walt RP, Pounder RK, Gomes MDFA, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24-hour decrease of intragastric acidity. Gut 1984; 25: 957-64.
32. Lind T, Cederberg C, Idstrom J-P, Lonroth H, Olbe L, Lundell L. 24-hour intragastric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in patients with reflux esophagitis. Scand J Gastroenterol 1991; 26: 620-6.
33. Lanzon-Miller S, Pounder RE, Hamilton MR, Chronos NAF, Ball S, Mercieca JE, et al. Twenty-four-hour intragastric acididty and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer, or pernicious anaemia. Aliment Pharmacol Ther 1987; 1: 225-37.
34. Lanas A, Hirschowitz B. Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol 1991; 13: 622-7.
35. Gotley D, Morgan A, Cooper M. Bile acid concentrations in the refluxate of patients with reflux oesophagitis. Br J Surg 1988; 75: 587-90.
36. Chiverton SG, Howden CW, Burget DW. Omeprazole (20mg) daily given in the morning or evening: a comparison of effects on gastric acidity, plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992; 6: 103-11.
37. Kuo B, Castell DO. Omeprazole 20mg bid provides better acid suppression than a single dose of 40mg. [Abstract]. Gastroenterology 1994; 106: A1034.